The publisher unveils its latest report on the Fluidic Devices market, forecasting robust growth in the industry. In 2024, the global fluidic devices market attained an impressive size of US$ 280 million. The market is projected to witness a substantial growth, surging to US$ 600 million by the close of 2031.
National Institutes of Health (NIH) Advancement: In 2022, NIH showcased the transformative impact of Artificial Intelligence (AI) on fluidic devices used in point-of-care clinical diagnostics. This innovation has paved the way for cost-effective polymer devices. An AI-controlled platform driven by an Android smartphone achieved real-time ELISA detection of the Human Cardiac Troponin I biomarker, with a detection limit of 0.98 pg/mL. This AI-driven revolution in fluidics holds immense promise.
Microfluidics and Nanofluidics Publication 2021: Researchers are actively developing a brain-on-a-chip (BoC) system, a miniaturized engineered platform, aiming to assess physiological data. This advancement holds promise for neuroscientists as it facilitates the study of axon properties, drug activity assessment, and examination of axonal regrowth following axotomy.
Why Fluidic Devices Thrive in the Life Sciences Industry?
'Data Precision & Accuracy in Point-of-care Diagnostics'
In the life sciences industry, the demand for precise and reliable data in diagnostics, drug discovery, and research has surged. Fluidic devices offer precise control over fluid flow, reaction conditions, and sample manipulation, ensuring reproducibility and reliability. Technological advances, including smart sensors, automation, and connectivity features, hold immense potential for real-time monitoring.
Nature Journal Article 2023: An article highlights the significance of fluidic technology, transforming mobile health platforms for early patient screening by integrating optical sensing and artificial intelligence analysis.
Early detection and personalized medicine fuel the medical diagnostics market, with fluidic devices meeting the escalating demand for faster, more accurate, and cost-effective solutions. Their ability to work with small sample quantities and perform multiplexed analysis aligns with the trend toward specialized and efficient screening and diagnostic methods.
The lack of interoperability between microfluidic devices and existing laboratory equipment poses a significant challenge to integrating microfluidics into established workflows and adopting them for routine drug screening and discovery processes. While fluidic approaches offer advantages, careful consideration of existing macroscopic approaches is essential.
Despite promising theoretical models and studies, only a limited number of lab-on-a-chip (LOC) systems are commercialized due to challenges in fabrication technology, manufacturing processes, and standardized practices. Standardization, improved fabrication techniques, and fault mode understanding are necessary to overcome these barriers.
Access to venture capital is vital for the growth of fluidic device start-ups, supporting early-stage development, innovation, talent acquisition, and product commercialization. Insufficient funding limits resources for research and development, manufacturing capabilities, marketing, and scaling operations.
Germany Market: Germany's market is expanding due to outpatient research focused on diagnostic precision in point-of-care devices and favorable healthcare policies that support medical technology.
Opportunities in China: China presents opportunities driven by a high prevalence of chronic diseases, increasing healthcare expenditure, and a growing demand for point-of-care diagnosis, particularly for conditions like diabetes, cancer, and cardiovascular disorders.
This product will be delivered within 1-3 business days.
Exploring Fluidic Devices: A Foundation for Scientific Advancement
Fluidics, a versatile field of study, encompasses a wide range of scientific applications, utilizing devices with microliter volumes or micrometer dimensions. These devices are crafted from diverse materials, influencing the flow, absorptivity, biocompatibility, and functionality of fluidic components.Empowering Point-of-Care Diagnostics
Fluidic devices play a pivotal role in advancing point-of-care diagnostics by offering miniaturized, portable, and user-friendly platforms for conducting a variety of diagnostic tests. By eliminating the need to send samples to centralized laboratories, point-of-care diagnostics reduce turnaround time for test results, proving efficient in resource-limited or remote settings. Microfluidic devices serve as the backbone of these on-site testing solutions.Enhancing Healthcare Through Early Detection and Monitoring
Integrated fluidic devices are instrumental in monitoring health parameters such as glucose levels, cholesterol, infectious diseases, and biomarkers. They enable early detection, continuous monitoring of chronic conditions, and preventive healthcare interventions. Timely diagnosis and early intervention are vital for improving patient outcomes, aiding healthcare professionals in informed treatment decisions and elevating patient care.National Institutes of Health (NIH) Advancement: In 2022, NIH showcased the transformative impact of Artificial Intelligence (AI) on fluidic devices used in point-of-care clinical diagnostics. This innovation has paved the way for cost-effective polymer devices. An AI-controlled platform driven by an Android smartphone achieved real-time ELISA detection of the Human Cardiac Troponin I biomarker, with a detection limit of 0.98 pg/mL. This AI-driven revolution in fluidics holds immense promise.
Applications Beyond Boundaries
Portable fluidic devices empower point-of-care diagnostics, offering miniaturized platforms for immediate test results, enabling swift diagnosis, and facilitating prompt treatment decisions. Researchers have reported the growing adoption of fluidic device innovations in detecting and treating a spectrum of malignancies in various vital organs, including the brain, lungs, heart, kidneys, gut, and skin.Microfluidics and Nanofluidics Publication 2021: Researchers are actively developing a brain-on-a-chip (BoC) system, a miniaturized engineered platform, aiming to assess physiological data. This advancement holds promise for neuroscientists as it facilitates the study of axon properties, drug activity assessment, and examination of axonal regrowth following axotomy.
Why Fluidic Devices Thrive in the Life Sciences Industry?
'Data Precision & Accuracy in Point-of-care Diagnostics'
In the life sciences industry, the demand for precise and reliable data in diagnostics, drug discovery, and research has surged. Fluidic devices offer precise control over fluid flow, reaction conditions, and sample manipulation, ensuring reproducibility and reliability. Technological advances, including smart sensors, automation, and connectivity features, hold immense potential for real-time monitoring.
Nature Journal Article 2023: An article highlights the significance of fluidic technology, transforming mobile health platforms for early patient screening by integrating optical sensing and artificial intelligence analysis.
Early detection and personalized medicine fuel the medical diagnostics market, with fluidic devices meeting the escalating demand for faster, more accurate, and cost-effective solutions. Their ability to work with small sample quantities and perform multiplexed analysis aligns with the trend toward specialized and efficient screening and diagnostic methods.
Challenges Hindering Fluidic Device Adoption
'Lack of Interoperability and Limited Access to Venture Capital'The lack of interoperability between microfluidic devices and existing laboratory equipment poses a significant challenge to integrating microfluidics into established workflows and adopting them for routine drug screening and discovery processes. While fluidic approaches offer advantages, careful consideration of existing macroscopic approaches is essential.
Despite promising theoretical models and studies, only a limited number of lab-on-a-chip (LOC) systems are commercialized due to challenges in fabrication technology, manufacturing processes, and standardized practices. Standardization, improved fabrication techniques, and fault mode understanding are necessary to overcome these barriers.
Access to venture capital is vital for the growth of fluidic device start-ups, supporting early-stage development, innovation, talent acquisition, and product commercialization. Insufficient funding limits resources for research and development, manufacturing capabilities, marketing, and scaling operations.
Country-wise Insights
United States Market: The U.S. market benefits from a well-established healthcare infrastructure and significant investments in microfluidic device production, giving firms a competitive advantage for global expansion.Germany Market: Germany's market is expanding due to outpatient research focused on diagnostic precision in point-of-care devices and favorable healthcare policies that support medical technology.
Opportunities in China: China presents opportunities driven by a high prevalence of chronic diseases, increasing healthcare expenditure, and a growing demand for point-of-care diagnosis, particularly for conditions like diabetes, cancer, and cardiovascular disorders.
Competition Landscape
The fluidic devices market is highly competitive, with both established players and new entrants contributing to its dynamism.Key Companies Covered:
- Cellix Ltd
- Elveflow
- Nortis Inc
- Fluigent SA
- Perkinelmer, Inc
- Fluidic Analytics
- Blacktrace Holdings Ltd (Dolomite Microfluidics)
- SynVivo, Inc
- Emulatebio
- Micronit B.V.
- Emerson Electric Co.
- LUMICKS
- microfluidic ChipShop GmbH
- Bartels Mikrotechnik GmbH
- LEE Ventus
- CETONI GmbH
- Christian Bürkert GmbH & Co. KG
- VWR International, LLC
- Harvard Apparatus
Key Segments of Fluidic Devices Industry Research
Product:
- Microchips
- Polymers
- Glass
- Silicon
- Ceramics
- Others
- Flow & Pressure Sensors
- Flow & Pressure Controllers
- Microfluidic Valves
- Micropumps/Microinjectors
- Syringe Microinjectors/Micropumps
- Peristaltic Pumps
- Pressure Microinjectors/Micropumps
- Others
- Microfluidic-based-Devices
- Organ-on-Chip
- TEER-on-Chip
- Other Components
Application:
- Disease Diagnostics
- Clinical Diagnostics
- Point-of-Care Testing
- Pharma & Life Science Research & Manufacturing
- Genomics
- Proteomics
- Drug Discovery & Development
- Capillary Electrophoresis
- Others (Micro Reactions, Microdispensing, etc.)
- Others (Forensics, Environmental, Food Safety, and Quality Control)
End User:
- Hospitals
- Diagnostic Centers
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Market Overview
3. Global Fluidic Devices Market Outlook, 2018 - 2031
4. North America Fluidic Devices Market Outlook, 2018 - 2031
5. Europe Fluidic Devices Market Outlook, 2018 - 2031
6. Asia Pacific Fluidic Devices Market Outlook, 2018 - 2031
7. Latin America Fluidic Devices Market Outlook, 2018 - 2031
8. Middle East & Africa Fluidic Devices Market Outlook, 2018 - 2031
9. Competitive Landscape
10. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Cellix Ltd.
- Elveflow
- Nortis Inc.
- Fluigent SA
- Perkinelmer, Inc.
- Fluidic Analytics
- Blacktrace Holdings Ltd.(Dolomite Microfluidics)
- SynVivo, Inc.
- Emulatebio
- Micronit B.V.
- Emerson Electric Co.
- LUMICKS
- microfluidic ChipShop GmbH
- Bartels Mikrotechnik GmbH
- LEE Ventus
- CETONI GmbH
- Christian Bürkert GmbH & Co. KG
- VWR International, LLC.
- Harvard Apparatus
Methodology
LOADING...
